Company Overview of Intrexon Corporation
Intrexon Corporation, a biotechnology company, operates in the synthetic biology field. Synthetic biology is a discipline that applies engineering principles to biological systems. The company designs, builds, and regulates gene programs, which are DNA sequences that consist of key genetic components using its proprietary and complementary technologies. Its proprietary and complementary technologies comprise UltraVector gene design and fabrication platform, which is an integrated suite of tools comprising DNA construction technology and components, cellular and protein engineering tools, computational models, and statistical methods; Cell systems informatics, a bioinformatics software and da...
222 Lakeview Avenue
West Palm Beach, FL 33401
Founded in 1998
Key Executives for Intrexon Corporation
Chief Operating Officer
Total Annual Compensation: $2.1M
Senior Vice President of Energy & Chemicals Sector and President of Industrial Products Division
Total Annual Compensation: $341.0K
Compensation as of Fiscal Year 2013.
Intrexon Corporation Key Developments
Intrexon Corporation and ZIOPHARM Oncology Announce Licensing Agreement with The University of Texas MD Anderson Cancer Center
Jan 14 15
Intrexon Corporation and ZIOPHARM Oncology announced a broad exclusive licensing agreement with The University of Texas MD Anderson Cancer Center, including an exclusive sublicensing agreement through MD Anderson for intellectual property developed at the University of Minnesota for the development of non-viral adoptive cellular cancer immunotherapies. The licensed technologies arise from the laboratory of Laurence Cooper, M.D., Ph.D., professor of pediatrics at MD Anderson and Perry Hackett, Ph.D., professor within the College of Biological Sciences at Minnesota. The Cooper and Hackett laboratories have pioneered the design and clinical investigation of novel chimeric antigen receptor (CAR) T cell therapies using non-viral gene integration platforms. MD Anderson has built on this technology to deliver patient-derived T cells, as well as innovative approaches to generating products for universal off-the-shelf applications. When combined with Intrexon’s technology suite and ZIOPHARM’s clinically tested RheoSwitch Therapeutic System® interleukin-12 modules, the resulting proprietary methods and technologies may help realize the promise of genetically modified CAR T cells by tightly controlling cell expansion and activation in the body, minimizing off-target effects and toxicity while maximizing therapeutic efficacy. Under the terms of the agreement, MD Anderson shall receive consideration of $100 million; $50 million from each Intrexon and ZIOPHARM, payable in shares of their respective common stock, as well as a commitment of $15 to $20 million annually over three years for researching and developing the technologies.
Intrexon Corporation Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-14-2015 08:30 AM
Jan 8 15
Intrexon Corporation Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-14-2015 08:30 AM. Venue: Westin St. Francis Hotel, San Francisco, California, United States. Speakers: Randal J. Kirk, Chairman, Chief Executive Officer and President.
Intrexon Corporation Appoints Peter Emtage as Vice President, Synthetic Immunology
Dec 4 14
Intrexon Corporation announced the appointment of Peter Emtage, Ph.D., as Vice President, Synthetic Immunology. Dr. Emtage will focus on further advancing the company's oncology and immunology platforms to bring the next generation of cellular-based solutions that overcome the limitations of current treatments and address the most challenging malignancies. Dr. Emtage brings to Intrexon over sixteen years of biologics development experience in the fields of oncology, autoimmunity, infectious diseases, and inflammation. Most recently, Dr. Emtage was Vice President of Immune Mediated Therapy in the Oncology Innovative Medicines group at Medimmune.
Similar Private Companies By Industry
Recent Private Companies Transactions